Overview of Resonate-2 clinical trial of ibrutinib in CLL

Overview of Resonate-2 clinical trial of ibrutinib in CLL

VJHemOnc

3 years
332 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).
Up Next Autoplay
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
Category: Acute Lymphoblastic Leukemia
1 Views
Cancer-News 29 minutes
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
Category: Chronic Lymphocytic Leukemia
1 Views
Cancer-News 32 minutes
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Category: Non-Hodgkin Lymphoma
2 Views
Cancer-News 33 minutes
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
Category: News
1 Views
Cancer-News 36 minutes
Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019
Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019
Category: News
5 Views
Cancer-News 37 minutes
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
Category: Multiple Myeloma
1 Views
Cancer-News 41 minutes
FerGene Announces Pivotal Phase 3 Study of Nadofaragene Firadenovec Met Its Primary Endpoint With More Than Half of Patients With High-Grade Non-Muscle Invasive Bladder Cancer (CIS ± Ta/...
FerGene Announces Pivotal Phase 3 Study of Nadofaragene Firadenovec Met Its Primary Endpoint With More Than Half of Patients With High-Grade Non-Muscle Invasive Bladder Cancer (CIS ± Ta/...
Category: News
0 Views
Cancer-News 43 minutes
The Leukemia & Lymphoma Society (LLS) and The American Society of Hematology (ASH) Team Up to Connect Blood Cancer Patients to Clinical Trials that Can Lead to New and Better Treatments
The Leukemia & Lymphoma Society (LLS) and The American Society of Hematology (ASH) Team Up to Connect Blood Cancer Patients to Clinical Trials that Can Lead to New and Better Treatments
Category: News
0 Views
Cancer-News 44 minutes
ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies
ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies
Category: General
0 Views
Cancer-News 45 minutes
Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition
Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition
Category: News
0 Views
Cancer-News 49 minutes